- FDA plans to keep Makary priorities on trials, China, deputy saysPHILADELPHIA – Following the recent departures of FDA Commissioner Marty Makary and both of his center directors for drugs and biologics, the Trump administration will continue pushing their priori…Endpoints · 1mo ago↗ source
- Takeda fortifies orexin potential with more Phase 3 dataWith a formidable new competitor set to enter the orexin development race, Takeda is out with new data that it hopes will reinforce market-leading potential. The additional results from Takeda’s…Endpoints · 1mo ago↗ source
- Elicio’s KRAS cancer vaccine fails in Phase 2, shares plummetElicio Therapeutics’ pancreatic cancer vaccine failed to improve outcomes in a mid-stage study, but the company is seeking funds to move ahead to a larger Phase 3 trial anyway. Elicio reported ...